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Background: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting b2-agonist combination therapy for COPD. We aimed to assess the
efficacy and safety of two strengths of FF/VI (100/25 mg; 50/25 mg) vs. individual components
(FF 100 mg, VI 25 mg) and placebo over 24 weeks.
Methods: Multicentre, randomised, placebo-controlled, double-blind, parallel-group study
of patients (N Z 1030) with moderate-to-severe COPD. All medication was administered
once daily in the morning. Co-primary efficacy endpoints were: (1) weighted mean (wm)
FEV1 (0e4 h post-dose on day 168) to assess acute lung function effects; and (2) trough
FEV1 (23e24 h post-dose on day 169) to assess long-lasting effects. Symptom-related
outcomes were analysed and adverse events (AEs) assessed.
Results: Main findings were: (1) the combination of FF/VI at a strength of 100/25 mg
significantly (p < 0.001) improved wm FEV1 (173 ml) and trough FEV1 (115 ml) vs. placebo. Si-
milar effects were observed with FF/VI 50/25 mg; (2) no significant difference was seen
between FF/VI 100/25 mg and VI 25 mg for trough FEV1 (48 ml, p Z 0.082), while an effect
was observed between FF/VI 100/25 mg and FF 100 mg for wm FEV1 (120 ml, p < 0.001); (3)
VI 25 mg over 24 weeks improved lung function vs. placebo significantly for wm FEV1 (103 ml,
p < 0.001) and trough FEV1 (67 ml, pZ 0.017); and (4) no safety signal was observed.1 858 1003.
thmaso.com (E.M. Kerwin).
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FF/VI 50/25 mg, 100/25 mg in COPD 561Conclusions: In subjects with moderate-to-severe COPD, FF/VI 100/25 mg provides rapid and
significant sustained bronchodilation at 24 weeks. Lung function is improved to a similar extent
with FF/VI 50/25 mg and to a somewhat lesser extent with VI 25 mg. All treatments were well
tolerated.
GSK study number: HZC112206.
ClinicalTrials.gov: NCT01053988.
ª 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
The combination of a long-acting b2-agonist (LABA) and
inhaled corticosteroids (ICS) is often used in the treatment
of patients with chronic obstructive pulmonary disease
(COPD).1,2 Currently available ICS/LABA combination ther-
apies require twice-daily dosing. This might reduce adher-
ence to therapy which, in turn, is associated with an
increased risk of hospitalisation and mortality.3
Fluticasone furoate (FF)/vilanterol (VI) is a novel ICS/
LABA combination with once-daily dosing administered via
a dry powder inhaler. FF is chemically distinct from fluti-
casone propionate4 and exhibits greater in vitro anti-
inflammatory potency and a longer duration of action.5 VI
is chemically distinct from salmeterol, is metabolised to
inert metabolites,6 and has been shown to have once-daily
dosing activity in COPD.7 To date, the combination of FF/VI
has been assessed in COPD subjects in a small 4-week
placebo-controlled safety study at a strength of 400/
25 mg8 and at strengths of 50/25 mg, 100/25 mg and 200/
25 mg in a small 4-week crossover study9; neither of these
studies assessed the contribution of the individual compo-
nents on efficacy.
The present study evaluated the efficacy and safety of
two strengths of FF/VI (50/25 mg and 100/25 mg) as com-
pared with the components (VI 25 mg and FF 100 mg; FF 50 mg
was not assessed as monotherapy) and placebo in a large
cohort of subjects with moderate-to-severe COPD over 24
weeks. The specific objectives of the present study were (1)
to assess the effects of two different strengths of FF/VI
(100/25 mg and 50/25 mg) on post-dose and trough forced
expiratory volume in the first second (FEV1); (2) to assess the
bronchodilatory effect of addition of FF to VI 25 mg; (3) to
confirm the once-daily bronchodilatory effect of VI 25 mg;
and (4) to assess the safety profile of all active treatments.
Methods
A detailed description of all methods is provided in the
Online Supplement.
Subjects and ethics
The study was conducted between October 2009 and Feb-
ruary 2011, at 221 centres in nine countries (Chile, Estonia,
Germany, Japan, Korea, Philippines, Poland, Russian Fed-
eration, and the United States). To be eligible, subjects
were required to be 40 years of age, have a clinical
diagnosis of COPD, a smoking history of 10 pack-years,
a post-bronchodilator FEV1/forced vital capacity (FVC)ratio of 0.70, a post-bronchodilator FEV1 70% predicted
(NHANES III), and a score of 2 on the Modified Medical
Research Council Dyspnoea Scale (mMRC). A history of
COPD exacerbations was not required for subjects to be
eligible to enter the study. Albuterol reversibility was
assessed at the screening visit, both reversible and non-
reversible subjects were eligible to enter the study.
Exclusion criteria included a current diagnosis of asthma
or other non-COPD respiratory disorders; lung volume
reduction surgery within 12 months of visit 1; poorly con-
trolled COPD, defined as acute worsening of COPD requiring
patient-managed therapy with corticosteroids or antibiotics
or treatment prescribed by a physician within 6 weeks prior
to visit 1; hospitalisation due to poorly controlled COPD
within 12 weeks prior to visit 1; a lower respiratory tract
infection that required the use of antibiotics within 6 weeks
prior to visit 1; the need for long-term oxygen therapy or
nocturnal oxygen therapy (12 h/day).
All subjects gave written informed consent and the
protocol was approved by the appropriate institutional re-
view boards and conducted in accordance with good clinical
practice guidelines and the Declaration of Helsinki.
Study design and treatments
This was a 24-week, multicentre, randomised, stratified (by
smoking status) placebo-controlled, double-blind, parallel-
group study (Fig E1; GlaxoSmithKline study number
HZC112206; ClinicalTrials.gov: NCT01053988). Subjects
were stratified by smoking status, with former smoker
defined as the subject having not smoked within the 6
months prior to the screening visit. At visit 1 (screening),
subjects entered a 2-week, single-blind run-in period dur-
ing which they received placebo once daily in the morning
via a dry powder inhaler that contains two strips. The
screening period was used to obtain a baseline assessment
of symptoms (breathlessness, cough, sputum production
and night-time awakenings requiring rescue medication
[albuterol/salbutamol]), rescue medication use and
adherence to therapy. Eligible subjects were then rando-
mised (1:1:1:1:1) to one of five double-blind treatments
comprising FF/VI 100/25 mg, FF/VI 50/25 mg, FF 100 mg, VI
25 mg (representing emitted doses of FF/VI 92/22 mg, FF/VI
44/22 mg, FF 92 mg and VI 22 mg) or placebo administered
once daily in the morning via dry powder inhaler (Glax-
oSmithKline, Ware, UK). The FF 100 mg arm was included to
demonstrate the contribution of VI 25 mg to the FF/VI
combination per regulatory requirements for registrational
studies. Similarly, VI 25 mg was included to demonstrate the
efficacy of this particular LABA as well as show the con-
tribution of FF to the FF/VI combination product. A central
562 E.M. Kerwin et al.randomisation schedule was generated using a validated
computerised system (RandAll; GlaxoSmithKline, London,
UK) and subjects were randomised using the Registration
and Medication Ordering System (RAMOS; GlaxoSmithKline,
London, UK) to register the subject, randomise the subject,
and receive medication assignment information. Subjects
withheld study medication on the morning of clinic visits
and rescue medication for at least 4 h prior to and during
clinic visits. Albuterol was allowed during the run-in and
treatment periods for use as symptom relief, as was ipra-
tropium bromide, provided the dose was a stable dosing
regimen from the screening visit onward. Other permitted
and prohibited medications are included in the Online
Supplement.
Efficacy measurements
Co-primary efficacy endpoints were: (1) weighted mean
(wm) FEV1 (0e4 h post-dose) on day 168, which assessed
the bronchodilatory effect of VI (vs. placebo) and as part of
the FF/VI combination (FF/VI 100/25 mg and FF/VI 50/25 mg
vs. placebo and FF/VI 100/25 mg vs. FF 100 mg); and (2)
change from baseline in trough (23e24 h post-dose) FEV1 on
day 169, which assessed the 24 h duration of action of FF/VI
and VI (vs. placebo) and determined the contribution of FF
50 or 100 mg to the long-lasting lung function effects of the
combination (FF/VI vs. VI). wm FEV1 (0e4 h) is derived by
calculating the AUC from FEV1 measured 5 min, 15 min,
30 min, 1, 2 and 4 h post-dose, and then dividing the AUC by
the time interval. The AUC is calculated using the tra-
pezoidal rule. It acts as a more robust measure of post-dose
lung function than peak FEV1.
Secondary efficacy endpoints were: (3) the change from
baseline (day 1) to day 168 in the level of dyspnoea (using
the Chronic Respiratory Questionnaire Self-Administered
Standardized (CRQ-SAS) dyspnoea domain); (4) peak FEV1
over the first 4 h post-dose on day 1 to assess maximal
bronchodilation; and (5) time to 100 ml improvement
from baseline over 0e4 h on day 1 to assess onset of action.
For the purposes of regulatory review the CRQ-SAS dysp-
noea domain was considered an ‘other’ endpoint by the US
Food and Drug Administration.
Finally, other endpoints analysed included: (6) the time
to 12% improvement in FEV1 over the first 4 h post-dose on
day 1; (7) wm FEV1 on days 1, 14, 56, and 84 and change
from baseline in trough FEV1 on days 2, 7, 14, 28, 56, 84,
112, and 140; (8) mean morning peak expiratory flow (AM
PEF) over the 24-week study period; (9) other symptom
related endpoints such as diary card records of cough,
sputum, and breathlessness (cough and sputum assessed on
a scale of 0e3, breathlessness assessed on a scale of 0e4
with 0 representing the absence of symptoms), rescue use
per 24-h period, and night-time awakenings requiring res-
cue treatment over the 24-week study period; and (10)
changes from baseline in the fatigue, emotional function,
mastery domains and total score of the CRQ-SAS.
Safety evaluation
Main safety endpoints were the incidence of adverse events
(AEs) and serious AEs (SAEs). A specific set of AEs weredefined a priori as those of special interest, based on AEs
known to be associated with ICS and/or LABA therapy. COPD
exacerbations, defined as moderate (acute worsening of
COPD requiring systemic corticosteroids and/or antibiotics)
or severe (requiring hospitalisation) and pneumonia were
also assessed; as were changes from baseline in pulse rate,
systolic blood pressure (BP), diastolic BP, 12-lead electro-
cardiogram (ECG) assessments (for heart rate and QT inter-
val corrected using Friedericia’s formula [QTcF]) and clinical
chemistry and haematology parameters (including glucose
and potassium levels). In two subsets of subjects, either
Holter reading assessments (nZ 475) or 24-h urinary cortisol
(UC) excretion (n Z 294; UC population) were obtained. An
oropharyngeal exam was conducted at each treatment visit
in all subjects. The Holter and UC populations were
recruited from selected sites to reduce the total burden of
assessments on individual patients and sites.
Spirometric measurements
Spirometry was performed using equipment that met or
exceeded the minimum performance recommendations of
the American Thoracic Society.10 Reference values were
those of NHANES III.11
Statistical analysis
Based on the standard deviation (SD) of 210 ml observed in
the previously reported VI dose-ranging study,7 considering
an a risk (two-sided) of 0.05, a sample size of at least 146
evaluable subjects per arm was required in order to have
90% power to detect a treatment difference between VI
or FF/VI vs. placebo of 100 ml for wm or trough FEV1 and
FF/VI vs. FF for wm FEV1 and to detect a treatment dif-
ference of 80 ml between FF/VI vs. VI for trough FEV1.
Based on prior trial experience, an expected withdrawal
rate of 27% was anticipated (GlaxoSmithKline: Data on
File). Hence, at least 200 subjects per arm (1000 subjects
planned to be randomised in total) were randomised.
Primary analyses were performed on the intent-to-treat
(ITT) population, which comprised all subjects randomised
to treatment and who had received at least one dose of
study medication. Change from baseline trough FEV1
recorded on days 2, 7, 14, 28, 56, 84, 112, 140, 168, and 169
was analysed using mixed model repeated measures
(MMRM) with covariates of baseline FEV1, smoking status
(stratum), day, centre grouping, treatment, day by baseline
interaction and day by treatment interaction, where day
was nominal. From this model, treatment differences were
obtained for each Day. wm FEV1 values recorded on Days 1,
14, 56, 84, and 168 were analysed similarly. CRQ-SAS was
analysed using the same methodology as the co-primary
endpoints, except the covariate of baseline dyspnoea
score replaced that of baseline FEV1. Peak FEV1 was ana-
lysed using analysis of co-variance with covariates of
baseline, smoking status, centre grouping and treatment.
Our study used two co-primary endpoints and 5 treat-
ment arms meaning 9 treatment comparisons of primary
interest. As such, even if there was no difference between
treatments, 5% of treatment comparisons might be expec-
ted to be significant purely by chance. This was controlled
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testing hierarchy (Fig. 1). Level 1 of the hierarchy com-
prised six key comparisons of the co-primary endpoints for
VI 25 mg and FF/VI 100/25 mg, each of which was equally
weighted. Significance with a p < 0.05 was required for all
of these comparisons to allow statistical significance to be
inferred for differences with p < 0.05 for co-primary end-
points for the FF/VI 50/25 mg strength. Inferences could
only be made for secondary endpoints if primary endpoints
were significant at the 5% level.Results
Subject characteristics
Of 1804 subjects screened, the ITT population comprised
1030 subjects who were randomised and received at least
one dose of treatment. 774 subjects were excluded at or
prior to randomisation, the majority of whom did not meet
the inclusion/exclusion criteria at screening (n Z 399) or
the continuation criteria at the end of the run-in period
(n Z 220). The majority of patients excluded at screening
were excluded due to severity of disease (n Z 347), while
the majority excluded at randomisation were excluded due
to 12-lead ECG (n Z 78) or Holter (n Z 86) findings. In
total, 723 (70%) subjects completed the study (Fig. 2).
Table 1 presents the demographic and clinical character-
istics at screening of study participants.
Efficacy: co-primary
We found that: (1) compared with placebo FF/VI 100/25 mg
significantly improved the adjusted mean wm FEV1 at day 168
by 173 ml (95% confidence interval [CI]: 123, 224; p < 0.001)
and the adjusted mean trough FEV1 at day 169 by 115 ml (95%
CI: 60, 169;p< 0.001); (2) comparedwithVI 25mg alone, FF/VIFigure 1 Statistical hierarchy. FEV1 Z forced expiratory
volume in first second, FF Z fluticasone furoate,
VI Z vilanterol, wm Z weighted mean.100/25 mg improved the adjustedmean trough FEV1 at day 169
by 48 ml (95% CI:6, 102), a difference which failed to reach
statistical significance (p Z 0.082) (Table 2). Furthermore,
compared with FF 100 mg alone, FF/VI 100/25 mg significantly
improved the adjusted mean wm FEV1 at day 168 by 120 ml
(95% CI: 7, 170; p < 0.001) (Table 2). The effects of FF/VI 50/
25 mg vs. placebo and vs. VI 25 mg on wm FEV1 and trough FEV1
(95% CI not including zero for these comparisons) were greater
than those of FF/VI 100/25 mg (Table 2), but due to the pre-
defined statistical hierarchy used in the analysis, no statisti-
cal inferencecanbedrawn fromthedifferencesobserved;and
(3) comparedwith placebo, VI 25 mg significantly improved the
adjustedmean wm FEV1 at day 168 by 103ml (95% CI: 52, 153;
p < 0.001) and the adjusted mean trough FEV1 at day 169 by
67ml (95% CI: 12, 121;pZ 0.017). Analysis of the per-protocol
population for the co-primary endpoints matched that of the
ITT population (data not shown).
Efficacy: secondary
The statistical hierarchy used in the analysis of results
(Fig. 1) meant that no significance could be inferred for
secondary endpoints. Thus, all differences reported can
only be regarded as descriptive.
For wm FEV1 at other time points over 24 weeks, both
strengths of FF/VI showed rapid and sustained improve-
ments over placebo, and were greater (95% CI not including
zero for these comparisons) than the VI monotherapy arm
at all time points from day 14 (Fig. 3). Similarly, both
combination strengths and VI showed rapid and sustained
effects on trough FEV1 compared with placebo, and both
combination strengths provided greater lung function ef-
fects than VI at days 7, 28, 56, 84, 140 and 168, but only the
50/25 mg strength provided greater lung function effects at
day 2, day 112 and day 169, and only the 100/25 mg strength
provided greater lung function effects at day 14 (Fig. 4).
There was no clear separation on either wm FEV1 or trough
FEV1 between the two strengths of FF/VI. Time course fig-
ures of wm FEV1 and trough FEV1 presented as differences
from placebo and active comparator (i.e. FF for wm FEV1
and VI for trough FEV1) are provided in Figs. E2 and E3.
No clinically meaningful difference (minimal important
difference0.5 units) for the CRQ-SAS dyspnoea domain was
seen for any active therapy vs. placebo, or combination at
either strength vs. component (Table 2). Peak FEV1 on day 1
was improved comparably in all arms containing VI 25 mg vs.
placebo (adjustedmean:139mle148ml). FF100mgalonehad
a minimal effect on peak FEV1 (Table 2). The time at which
50% subjects (median time) achieved 100 ml improvement
in FEV1 from baseline on day 1 was 16 min for VI 25 mg and
17 min for both strengths of FF/VI. No median time could be
determined for placeboor FF 100mg as insufficient subjects in
each arm had achieved 100 ml improvement by 4 h on day 1.
Serial FEV1 on days 1 and 168 showed both combinationswere
approximately the same as VI on day 1, but showed numerical
improvements over VI by day 168 (Fig. E4).Efficacy: other outcomes
Diary card and CRQ-SAS symptom data for all treatments
and comparisons are presented in Table E1. FF/VI 50/25 mg
Figure 2 Consort diagram. FF Z fluticasone furoate, ITT Z intent-to-treat, VI Z vilanterol.
564 E.M. Kerwin et al.and 100/25 mg showed greater improvements compared
with placebo (95% CI not including zero) in diary card
symptoms, rescue use or rescue-free 24-h periods, night-
time awakenings and morning peak flow. CRQ-SAS scores
were only greater than placebo with the FF/VI 100/25 mg
strength for the fatigue domain and total score. According
to the hierarchy of analysis, statistical significance could
not be inferred for any comparisons of ‘other’ outcomes.
Safety
The incidence of on-treatment AEs was higher with active
therapy vs. placebo; but the reports of SAEs were similar
across arms (Table 3). Nasopharyngitis was the most com-
monly reported AE in all treatment arms, except FF/VI 50/
25 mg where upper respiratory tract infection was the most
reported event (Table 3). Local steroid effects, reported as
oropharyngeal candidiasis, oral candidiasis, oropharyngeal
pain, dysphonia, throat irritation, oropharyngitis fungal or
candidiasis, were noted in 6e12% of subjects in the FF
containing arms vs. 3% in the placebo and VI 25 mg arms.
Other AEs of special interest were reported by similar
numbers of subjects in all treatment arms (Table 3). Drug-
related on-treatment AEs (Table E2) on-treatment SAEs
(Table E3) and AEs/SAEs leading to withdrawal of study
treatment or discontinuation from the study (Table E4) are
provided in the Online Supplement.
During the 26 weeks of study period, COPD exacerbations
(the majority of which were moderate) occurred in 6e9% of
subjects receiving combination therapy and in 10e13% of
subjects receiving placebo, or FF or VI 25 mg alone. Fewsubjects in any treatment arm had severe exacerbations in
this 24-week study. Pneumonia occurred infrequently in
each arm and none of the pneumonias recorded resulted in
fatality (Table E5). Chest x-rayswere performed for 16 of the
20 pneumonias, of these 13 showed infiltrates.
No abnormality of potential clinical concern was recor-
ded for clinical chemistry or haematology parameters over
the course of the study, nor was any treatment effect
observed on blood levels of potassium or glucose. Analysis
of the day 168 baseline ratio of UC (UC population) excre-
tion compared with placebo showed no clinical effect of
any treatment on this parameter (Fig. E5). QTcF and ECG
heart rate were assessed post-dose on days 1 and 84 and
pre-dose on days 1, 84 and 168, and compared with placebo
no clinical difference was observed from baseline in either
of these measures (Figs. E6 and E7).
A total of 2 deaths were reported during pre-treatment
(cardiac arrest during pre-screening and run-in), 3 during
the treatment period (1 subject in the VI arm died of sud-
den cardiac death, and 2 subjects in the FF/VI 50/25 mg
therapy died, 1 due to cerebral haemorrhage with alcohol
poisoning and 1 due to gastrointestinal haemorrhage); and 2
during follow-up (sudden death in the placebo arm and
pulmonary embolism in the FF 100 mg arm). None of the
deaths were considered to be drug-related by the local
investigator.
Discussion
The main findings of this study are that: (1) the combination
of FF/VI at strengths of 50/25 mg and 100/25 mg improves











Age, yr (SD) 62.1 (8.80) 62.7 (9.47) 63.4 (9.58) 62.8 (9.13) 62.3 (8.49)
Male sex, n (%) 141 (68) 132 (64) 140 (68) 135 (66) 137 (67)
Race, n (%)
White 155 (75) 139 (67) 141 (69) 156 (76) 150 (73)
Asian 44 (21) 64 (31) 57 (28) 43 (21) 46 (22)
Other 8 (4) 3 (1) 7 (3) 7 (3) 10 (5)
Current smoker, n (%) 112 (54) 111 (54) 111 (54) 111 (54) 111 (54)
Smoking history, pack-yr (SD) 45.6 (25.0) 46.2 (25.3) 47.6 (28.1) 44.2 (25.4) 46.6 (25.1)
COPD type, n (%)
Chronic bronchitis 128 (62) 116 (56) 132 (65) 122 (59) 127 (62)
Emphysema 127 (61) 140 (68) 127 (62) 141 (68) 135 (66)
Pre-study COPD therapy, n (%)
SABA 113 (55) 120 (58) 114 (56) 106 (51) 115 (56)
SAMA 85 (41) 79 (38) 66 (32) 65 (32) 66 (32)
LABA 70 (34) 67 (33) 67 (33) 63 (31) 67 (33)
LAMA 56 (27) 58 (28) 54 (26) 49 (24) 50 (24)
ICS 45 (22) 45 (22) 52 (25) 48 (23) 48 (23)
On-treatment non-COPD medication, n (%) 174 (84) 163 (79) 161 (79) 169 (82) 162 (79)
Screening pre-BD FEV1, l (SD) 1.261 (0.4467) 1.166 (0.4286) 1.285 (0.4716) 1.234 (0.4731) 1.246 (0.4952)
Screening post-BD FEV1, l (SD) 1.448 (0.4682) 1.320 (0.4365) 1.442 (0.4766) 1.409 (0.4966) 1.410 (0.5018)
Screening % predicted pre-BD FEV1, % (SD) 42.4 (12.80) 41.5 (13.13) 44.5 (12.78) 42.5 (12.78) 42.3 (12.74)
Screening % predicted post-BD FEV1, % (SD) 48.5 (12.46) 46.9 (12.73) 49.9 (12.05) 48.4 (12.66) 47.8 (12.28)
Screening FEV1 reversibility, ml (SD) 184.6 (152.31) 153.7 (176.78) 155.6 (152.62) 171.6 (158.31) 160.0 (159.92)
Reversible at screeninga, n (%) 77 (38) 71 (34) 64 (31) 73 (36) 66 (32)
Screening mMRC dyspnoea score, units (SD) 2.3 (0.55) 2.4 (0.54) 2.3 (0.49) 2.3 (0.51) 2.4 (0.59)
Moderate exacerbation in the year prior to screening, n (%)
0 163 (79) 156 (76) 152 (74) 156 (76) 160 (78)
1 44 (21) 50 (24) 53 (26) 50 (24) 46 (22)
Severe exacerbation in the year prior to screening, n (%)
0 196 (95) 187 (91) 189 (92) 195 (95) 192 (93)
1 11 (5) 19 (9) 16 (8) 11 (5) 14 (7)
Moderate exacerbation required oral/systemic corticosteroids and/or antibiotics but did not involve hospitalisation; severe exacer-
bation required hospitalisation; BDZ twice daily, COPDZ chronic obstructive pulmonary disorder, FEV1Z forced expiratory volume in
the first second, FF Z fluticasone furoate, ICS Z inhaled corticosteroids, LABA Z long-acting b2-agonist, LAMA Z long-acting
muscarinic-antagonists, mMRC Z Modified Medical Research Council Dyspnoea Scale, SABA Z short-acting b2-agonist, SAMA Z short-
acting muscarinic-antagonists, SD Z standard deviation, VI Z vilanterol.
a Reversible to albuterol/salbutamol as defined by 12% and 200 ml improvement in FEV1 post-dose.
FF/VI 50/25 mg, 100/25 mg in COPD 565both post-dose and trough FEV1 compared with placebo;
the improvement with the 100/25 mg strength was statis-
tically significant; the improvement was even greater,
numerically, with the 50/25 mg strength but this improve-
ment cannot be regarded as statistically significant due to
the statistical hierarchy employed; (2) differences between
FF/VI at either strength and VI 25 mg were not statistically
significant; (3) VI 25 mg, dosed once daily over 24 weeks,
significantly improves both post-dose and trough FEV1 vs.
placebo; and (4) no safety signal was observed.
Our results confirm the once-daily bronchodilatory ef-
fect of VI, which has previously only been assessed over 28
days.7 Prior studies of twice-daily ICS/LABA combinations
have shown a significant effect of the combination over the
ICS component alone for post-dose FEV1,
12e17 as also shown
here. In most,12,13,16 but not all previous studies,17 a sig-
nificant effect for the combination over the LABA alone on
pre-dose/trough FEV1 has also been observed, indicatingthe contribution of each component to the combination. In
the present study we found numerical differences of 48 ml
or 62 ml between FF/VI at strengths of 100/25 mg or 50/
25 mg and VI 25 mg for trough FEV1. However, the treatment
difference was smaller in magnitude than anticipated when
designing the trial. Furthermore, the actual variability was
larger than that assumed in the sample size calculation.
The present study was designed to confirm the bron-
chodilatory effect of VI 25 mg and to investigate the bron-
chodilatory effect of FF/VI combination therapy. We found
that VI 25 mg alone did not meet the suggested minimal
clinically important difference (MCID) of 100 ml vs. placebo
for trough FEV1.
18 However, both strengths of FF/VI did
achieve the suggested MCID, suggesting a clinically impor-
tant effect for the combination. The study also allowed us
to investigate whether a doseeresponse was observed be-
tween the 50/25 mg and 100/25 mg strengths of FF/VI, and it
is apparent that no doseeresponse to the FF component
Table 2 Primary and secondary study endpoint comparisons.
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0.173* (0.123, 0.224) 0.115* (0.060, 0.169) 0.30 (0.06, 0.54) 0.139 (0.112, 0.166)
FF/VI 100/25 mg
vs. VI 25 mg
0.071 (0.021, 0.121) 0.048*** (0.006, 0.102) 0.16 (0.08, 0.40) 0.003 (0.030, 0.025)
FF/VI 100/25 mg vs.
FF 100
0.120* (0.070, 0.170) 0.082 (0.028, 0.136) 0.24 (0.01, 0.48) 0.127 (0.100, 0.154)
FF 100 mg vs. PBO 0.053 (0.003, 0.104) 0.033 (0.022, 0.088) 0.06 (0.18, 0.30) 0.012 (0.015, 0.039)
FF 50 comparisons
FF/VI 50/25 vs. PBO 0.192 (0.141, 0.243) 0.129 (0.074, 0.184) 0.19 (0.05, 0.43) 0.148 (0.120, 0.175)
FF/VI 50/25 mg vs.
VI 25 mg
0.090 (0.039, 0.140) 0.062 (0.008, 0.117) 0.05 (0.19, 0.29) 0.006 (0.022, 0.033)
Values are differences in least square mean (95% CI); FEV1 is expressed in Litres; CRQ-SAS Z Chronic Respiratory Questionnaire Self-
Administered Standardized, FEV1 Z forced expiratory volume in the first second, FF Z fluticasone furoate, PBO Z placebo,




a Peak FEV1 represents maximum post-dose FEV1 from assessments taken at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h post-dose. CRQ-SAS
dyspnoea domain is scaled from 0 to 7, with 0 indicating no impairment; the minimal important difference for change is 0.5 units.
566 E.M. Kerwin et al.was observed for comparison of the wm or trough FEV1
endpoints. Of note, FF/VI dosed once daily at the strength
of 100/25 mg has been shown to exhibit similar lung function
efficacy to the combination of fluticasone propionate/sal-
meterol, dosed twice daily at a strength of 500/50 mg in
patients with moderate to severe COPD.19 In the present
study both strengths of the combination therapy exhibited
sustained bronchodilatory effects over the course of the
study, while for VI 25 mg alone a slight waning of effect was
observed for both post-dose and trough FEV1. Whether thisFigure 3 Least squares weighted mean (0e4 h) FEV1 from
day 1 to day 168. CI Z confidence interval, FEV1 Z forced
epiratory volume in first second, FF Z fluticasone furoate,
LS Z least squares, VI Z vilanterol, wm Z weighted mean.represents the development of tolerance to the broncho-
dilatory effect of VI 25 mg or is a consequence of the natural
decline in lung function in our population of moderate-to-
severe COPD patients is unclear. Notably, however, toler-
ance to LABAs in COPD is not observed, as compared with
asthma where combination treatment with an ICS is
required to offset the development of tolerance.20
The FF/VI 100/25 mg/VI 25 mg comparison for trough FEV1
was part of the pre-specified hierarchy, and failure to ach-
ieve significance at this comparison meant that p-values forFigure 4 Least squares mean trough FEV1, change from
baseline from day 2 to day 169. CI Z confidence interval,
FEV1 Z forced expiratory volume in first second,
FF Z fluticasone furoate, LS Z least squares, VI Z vilanterol.












Any on-treatment AEs 100 (48) 123 (60) 111 (54) 114 (55) 111 (54)
AEs leading to permanent discontinuation from the
study or withdrawal of study treatmenta
19 (9) 25 (12) 27 (13) 19 (9) 18 (9)
Any on-treatment SAEs 11 (5) 16 (8) 15 (7) 6 (3) 11 (5)
Any on-treatment fatal SAEs 0 0 1 (<1) 2 (<1) 0
AEs of special interest
Cardiovascular effects 16 (8) 18 (9) 15 (7) 15 (7) 11 (5)
Local steroid effects 7 (3) 13 (6) 6 (3) 24 (12) 16 (8)
LRTI excluding pneumonia 8 (4) 8 (4) 6 (3) 3 (1) 5 (2)
Pneumonia 3 (1) 4 (2) 5 (2) 3 (1) 5 (2)
Hypersensitivity 2 (<1) 5 (2) 3 (1) 1 (<1) 6 (3)
Effects on glucose 1 (<1) 4 (2) 1 (<1) 3 (1) 5 (2)
Bone disorders 4 (2) 2 (<1) 2 (<1) 1 (<1) 1 (<1)
Ocular effects 1 (<1) 1 (<1) 1 (<1) 1 (<1) 1 (<1)
Systemic steroid effects 2 (<1) 0 0 2 (<1) 1 (<1)
Effects on potassium 1 (<1) 1 (<1) 0 0 0
Tremor 0 1 (<1) 0 0 0
All on-treatment AEs occurring in 3% of subjects in any treatment group
Nasopharyngitis 14 (7) 18 (9) 22 (11) 14 (7) 22 (11)
Upper respiratory tract infection 8 (4) 13 (6) 11 (5) 16 (8) 21 (10)
Headache 5 (2) 17 (8) 16 (8) 12 (6) 18 (9)
Back pain 4 (2) 5 (2) 7 (3) 7 (3) 6 (3)
Oropharyngeal candidiasis 2 (<1) 4 (2) 2 (<1) 10 (5) 6 (3)
Oral candidiasis 1 (<1) 2 (<1) 3 (1) 8 (4) 4 (2)
Cough 6 (3) 5 (2) 1 (<1) 3 (1) 6 (3)
Sinusitis 2 (<1) 7 (3) 3 (1) 1 (<1) 4 (2)
Lower respiratory tract infection 7 (3) 1 (<1) 4 (2) 3 (1) 1 (<1)
Chronic obstructive pulmonary disease 3 (1) 2 (<1) 6 (3) 0 4 (2)
Arthralgia 2 (<1) 7 (3) 2 (<1) 1 (<1) 2 (<1)
Oropharyngeal pain 3 (1) 6 (3) 0 2 (<1) 2 (<1)
a Includes on-treatment and post-treatment. AEs Z adverse events, FF Z fluticasone furoate, LRTI Z lower respiratory tract
infection, SAEs Z serious adverse events, VI Z vilanterol.
FF/VI 50/25 mg, 100/25 mg in COPD 567comparisons of secondary and other endpoints were regar-
ded as descriptive only. Despite this testing hierarchy, no
clinically important effects of any active therapy were
observed on the CRQ-SAS dyspnoea domain, indicating the
lung function benefits observed did not translate to an
improvement in breathlessness, as measured by the CRQ-
SAS. A similar lack of response on the CRQ-SAS dyspnoea
domain has also been observed in GOLD grade II/III patients
with similar baseline levels of dyspnoea treated with fluti-
casone propionate/salmeterol or fluticasone propionate/
salmeterol þ tiotropium.21 In that study too, an improve-
ment in lung function (with fluticasone propionate/
salmeterol þ tiotropium vs. fluticasone propionate/salme-
terol) did not translate to an improvement in the perception
of dyspnoea as measured by the CRQ-SAS. As compared with
the 50/25 mg strength, numerical benefits of the FF/VI 100/
25 mg strength over placebo and VI 25 mg were observed for
other symptomatic endpoints such as rescue medication
use. However, these differences are descriptive only and any
benefit of adding FF to VI 25 mg will require further assess-
ment. The primary effect of the ICS component of COPD
combination therapy is to reduce the occurrence of exac-
erbations and control symptoms,1,2 effects which are bestinvestigated in studies of1 year in duration. Our study was
shorter than this, so no firm conclusions can be drawn with
respect to the occurrence of exacerbations (see below).
An increase in drug-related AEs was observed with active
therapy relative to placebo, though no clear signal was
discernible for SAEs. For AEs known to be associated with
chronic LABA or ICS therapy no substantial signal was
observed with active therapy relative to placebo, except
for local corticosteroid events in those arms featuring FF,
where no evidence of a dose effect was observed. The
majority of local steroid events comprised oral candidiasis;
yet, it must be considered that an oropharyngeal exami-
nation was conducted at each study visit and that this does
not typically represent routine practice. The incidence of
exacerbations was low in this 24-week study, potentially as
a consequence of subjects not having to exhibit a history of
exacerbations to be eligible for the study. As such, and as
our study was not designed or powered to examine exac-
erbations from an efficacy perspective, this finding should
be interpreted with caution. Similarly, while the incidence
of pneumonia (none of which were fatal) was low overall
and no trend was observed for an increase in the presence
of FF, additional prospective data are required to
568 E.M. Kerwin et al.determine any risk of this event with FF in COPD patients.
No clinically meaningful effects on UC excretion, another
potential effect of ICS treatment, nor QTcF or heart rate,
established potential effects of LABA treatment, were
observed. The latter is particularly relevant as the study did
not exclude subjects on any co-medication with the po-
tential to adversely affect the QTcF interval.
Our study has several strengths and limitations that
deserve comments. First, it was conducted in a clinically
appropriate cohort of subjects, assessed appropriate lung
function endpoints, and was of sufficient length to allow
clinically meaningful conclusions to be drawn regarding the
bronchodilatory effects of the combination and its compo-
nents. Second, the statistical hierarchy used represents both
a strength and potential limitation. While it is a robust
methodology to account for multiplicity, it also means that,
in this study, statistical significance cannot be inferred for
the co-primary endpoint assessments of FF/VI 50/25 mg and
all secondary and other endpoints. Finally, only data from
the dyspnoea domain of the CRQ-SAS was assessed as a sec-
ondary endpoint, limiting interpretation of other potential
symptomatic effects of the combination or its components.
In conclusion, this study shows that in patients with
moderate-to-severe COPD, FF/VI provides significant, sus-
tained bronchodilation at 24 weeks with a rapid onset of
action; that the effects obtained with addition of either
strength of FF (100 mg or 50 mg) were similar to those with VI
25 mg alone; and that all treatments were well tolerated.
Overall, the totality of the data indicate FF/VI at strengths
of both 50/25 mg or 100/25 mg represents a potential once-
daily maintenance therapy for moderate-to-severe COPD.
Longer term studies are required to determine the effects
of these two strengths on other important COPD outcomes
such as exacerbations.Acknowledgements
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